This is probably about as good as you're going to get right now bud. Now, are the below epidemiologists and disease specialists expert enough for you?
“We cannot draw definitive conclusions from these data, but the observations from this group of hospitalized patients who received remdesivir are hopeful,” said Jonathan Grein, lead author of the analysis and director of hospital epidemiology at Cedars-Sinai Medical Center in Los Angeles, in a statement from Gilead. “We look forward to the results of controlled clinical trials to potentially validate these findings.”
“Results are indeed hopeful and promising from this uncontrolled remdesivir intervention study,”
tweeted Eric Feigl-Ding, an epidemiologist and health economist at the Harvard T. H. Chan School of Public Health. “TRIALS TRIALS TRIALS PLEASE,” he added.
Paul Goepfert, an infectious disease specialist at the University of Alabama at Birmingham,
told the Washington Post that “It’s still a promising drug, but it doesn’t definitively prove anything.” He added, “The main thing you can gather from this study is it doesn’t cause any untoward harm.”
Remdesivir looks “hopeful” but hydroxychloroquine has some worrying side effects.
www.vox.com